Hence, it might be worthwhile to explore if the repurposing of anti-CD33 antibodies/inhibitors developed for treating acute myelogenous leukemia (Gemtuzumab ozogamicin, Vadastuximab talirine, Lintuzumab, BI-836858, HuM195/rGel and HuM-195-Ac-225) are also effective for AD. This evidence concerns the gene CD33 and acute myeloid leukemia.